Soft Tissue Sarcoma Adult Clinical Trial
Official title:
Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy
Combined treatment of soft tissue sarcoma includes 3 steps:
1. step - preoperative stereotactic radiation therapy in hypofractionation mode
2. step - operation
3. step - postoperative conformal radiation therapy in normofractionation mode
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 1, 2028 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - morphologically verified diagnosis of soft tissue sarcoma - first diagnosed tumor process - ability to perform radical surgery - signed informed consent - indications for stereotactic and conformal radiation therapy - no contraindications for radiation and surgical treatment Exclusion Criteria: - previous radiation treatment - acute infection - pregnancy, lactation - recurrent tumor - refuse to sign informed consent - conditions that can affect the outcome of treatment (immunodeficiency, tuberculosis, etc.) - tumor topography and volume that don't allow to perform stereotactic and conformal radiation therapy. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | National Research Center of Oncology named after N.N.Petrov | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
N.N. Petrov National Medical Research Center of Oncology |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complications | Rate of complications will be measured after completing each step of protocol: stereotactic radiation therapy, surgery and them postoperative conformal radiation therapy | 3 year | |
Secondary | Disease-Free survival | Disease-Free survival will be evaluated after completing the protocol or during the protocol if local recurrence will appear. | 3 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04656262 -
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
|
Phase 3 | |
Recruiting |
NCT03077178 -
Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over
|
N/A | |
Not yet recruiting |
NCT06110650 -
A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma
|
N/A | |
Terminated |
NCT03735758 -
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
|
Phase 4 | |
Not yet recruiting |
NCT03951571 -
Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
|
Phase 2 | |
Enrolling by invitation |
NCT03134742 -
Radiation Effects on Bone
|
||
Not yet recruiting |
NCT06252727 -
Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)
|
Phase 1 | |
Recruiting |
NCT04617327 -
Pre-operative RadiothErapy for Soft Tissue SarcOmas
|
N/A | |
Recruiting |
NCT06385288 -
Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT05116254 -
Sarcomas and DDR-Inhibition; a Combined Modality Study
|
Phase 1 | |
Active, not recruiting |
NCT03526679 -
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04008238 -
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
|
N/A | |
Recruiting |
NCT04095208 -
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
|
Phase 2 | |
Completed |
NCT03833037 -
Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
|
||
Completed |
NCT03056599 -
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
|
Phase 1 | |
Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
Recruiting |
NCT06273852 -
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
Withdrawn |
NCT03104335 -
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
|
Phase 2 |